Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Budesonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 13/20 | 0.86 |
| ▸ | PGR | P06401 | 8/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.86 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.86 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.86 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.86 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.86 |
| ▸ | IL5 | P05113 | 1/20 | 0.86 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.86 |
| ▸ | AR | P10275 | 1/20 | 0.86 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.86 |
| ▸ | MMP9 | P14780 | 1/20 | 0.86 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.86 |
| ▸ | THPO | P40225 | 1/20 | 0.86 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.86 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.86 |
| ▸ | LMNA | P02545 | 1/20 | 0.86 |
| ▸ | BLM | P54132 | 1/20 | 0.86 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Budesonide SCHEMBL19583458 | 1.00 | NR3C1 (0.86) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL3305268 | 1.00 | NR3C1 (0.86) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL3300565 | 0.96 | NR3C1 (0.80) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL19741553 | 0.96 | NR3C1 (0.80) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL3304441 | 0.96 | NR3C1 (0.80) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL14965921 | 0.95 | NR3C1 (0.93) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL5396843 | 0.93 | NR3C1 (0.94) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL6059521 | 0.93 | NR3C1 (0.94) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL4448854 | 0.93 | NR3C1 (0.97) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL13871728 | 0.93 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109152735-B | Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2022-03-11 | — | — | CN | claimed |
| EP-3454835-B1 | LIPID NANOPARTICLES COMPRISING LIPOPHILIC ANTI-INFLAMMATORY AGENTS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2021-03-31 | — | — | EP | claimed |
| EP-3454835-A1 | LIPID NANOPARTICLES COMPRISING LIPOPHILIC ANTI-INFLAMMATORY AGENTS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2019-03-20 | — | — | EP | claimed |
| CN-109152735-A | Lipidic nanoparticles and its application method comprising lipophilicity anti-inflammatory agent | 阿斯利康(瑞典)有限公司 | 2019-01-04 | — | — | CN | claimed |
| US-20170367988-A1 | LIPID NANOPARTICLES COMPRISING LIPOPHILIC ANTI-INFLAMMATORY AGENTS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2017-12-28 | — | — | US | claimed |
| WO-2017194454-A1 | LIPID NANOPARTICLES COMPRISING LIPOPHILIC ANTI-INFLAMMATORY AGENTS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2017-11-16 | — | — | WO | claimed |
| CN-109152735-B | Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3454835-B1 | LIPID NANOPARTICLES COMPRISING LIPOPHILIC ANTI-INFLAMMATORY AGENTS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2021-03-31 | — | — | EP | disclosed |
| EP-3454835-A1 | LIPID NANOPARTICLES COMPRISING LIPOPHILIC ANTI-INFLAMMATORY AGENTS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2019-03-20 | — | — | EP | disclosed |
| CN-109152735-A | Lipidic nanoparticles and its application method comprising lipophilicity anti-inflammatory agent | 阿斯利康(瑞典)有限公司 | 2019-01-04 | — | — | CN | disclosed |
| US-20170367988-A1 | LIPID NANOPARTICLES COMPRISING LIPOPHILIC ANTI-INFLAMMATORY AGENTS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2017-12-28 | — | — | US | disclosed |
| WO-2017194454-A1 | LIPID NANOPARTICLES COMPRISING LIPOPHILIC ANTI-INFLAMMATORY AGENTS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2017-11-16 | — | — | WO | disclosed |